A share of "medical first brother" was transferred, and the company responded to the normal change

[pharmaceutical network enterprise news] recently, sun piaoyang, the soul of Hengrui pharmaceutical, the "first pharmaceutical brother" of A-share, ceased to be the chairman of the board of directors, which attracted extensive attention of investors On the evening of January 16, Hengrui pharmaceutical announced that the eighth board meeting of the company was held in Shanghai in the form of on-site meeting on January 16 On the same day, the meeting passed the proposal on the election of the chairman of the 8th board of directors of the company: Zhou Yunshu was elected as the chairman of the 8th board of directors of the company After this meeting, sun piaoyang served as a director and chairman of the strategic committee of the company, and no longer served as chairman of the board Sun piaoyang, 61, has been the chairman of Jiangsu Hengrui Pharmaceutical Co., Ltd since 1997 He has been at the helm of Hengrui for nearly 30 years, leading Hengrui to transform from generic medicine to innovative medicine, continuously increasing R & D investment, and creating the current A-share private innovative medicine R & D brother and market value brother In 2018, Hengrui pharmaceutical has invested 2.67 billion yuan in R & D, accounting for 15.33% of the sales revenue; in the first three quarters of 2019, the R & D investment is as high as 2.899 billion yuan, accounting for 17.1% of the sales volume, and it is expected that the R & D investment and proportion will reach a new high in the year In terms of research and development achievements, in 2018-2019 alone, Hengrui pharmaceutical has three innovative drugs on the market In 2019, the first-line clinical study of the innovative drug of Hengrui, carrelizumab and apatinib mesylate, in the treatment of advanced HCC stage III, has been carried out in 14 countries and regions, including the United States, Europe and China, and 123 centers In 2020, Hengrui announced the approval of 1.1 innovative drug rimazolum toluene sulfonate for injection Up to now, Hengrui pharmaceutical has 6 innovative drugs on the market, and another batch of innovative drugs are in the clinical development stage, basically forming the development trend of applying for clinical innovative drugs every year and listing innovative drugs every 1-2 years Hengrui medicine has long been regarded as a good choice by the organization It took Hengrui Pharma 16 years from listing to breaking through the market value of 100 billion yuan; on October 28, 2019, Hengrui Pharma closed at the price of 91.08 yuan / share, breaking through the market value of 400 billion yuan As of January 16, 2020, the stock price of Hengrui Pharmaceutical Co., Ltd is 86.44 yuan, with a total market value of over 382.3 billion yuan With the share price rising, sun's fortune is also rising According to the Forbes rich list in 2019, the sun piaoyang family, who controls Hengrui pharmaceutical / Hansen pharmaceutical, ranks fourth on the Forbes rich list in 2019 with a wealth of 182.43 billion yuan, an increase of 110.67 billion yuan over the wealth value when it was listed in 2018 Sun piaoyang, the "soul figure" of Hengrui medicine, was appraised in the announcement as follows: "Mr Sun piaoyang led Hengrui to achieve sustainable and healthy development The board of directors of the company expresses sincere thanks and high respect to Mr Sun piaoyang for his contribution and hard work to Hengrui's development " Hengrui related people told the media that the "change" is actually a very normal change "When he is old, he hopes to focus more on the company's future strategy, and the operation work will be handed over to the professional manager team, which has been preparing for several years ago." His successor, Zhou Yunshu, is also the elder of Hengrui According to the announcement of Hengrui pharmaceutical, Zhou Yunshu graduated from China Pharmaceutical University in 1995 and has worked in Jiangsu Hengrui Pharmaceutical Co., Ltd since 1995 He has successively served as deputy director, deputy general manager, general manager and director of the development department In addition, according to relevant personnel of Hengrui pharmaceutical, after the board of directors changes, in addition to the chairman and general manager, the personnel and division of labor of the senior management team of Hengrui pharmaceutical have not changed much, and they still perform their respective duties.